普健生物(武汉)科技有限公司 服务热线: 18162686757
 
公司首页 公司介绍 公司动态 产品展厅 证书荣誉 联系方式 在线留言
 
 
PRODUCT产品展厅
Certolizumab ELISA Kit(赛妥珠单抗 )
  • 品牌:abinscience
  • 产地:France
  • 型号:96T
  • 货号:DF879028
  • 价格: ¥6756/盒
  • 发布日期: 2025-04-16
  • 更新日期: 2025-04-30
产品详请
产地 France
保存条件
品牌 abinscience
货号 DF879028
用途 供科研使用
检测方法 Colorimetric
保质期 1 year
适应物种 Not Species Specific
检测限
数量 999
包装规格 96T
标记物 Unconjugated
样本 Plasma, Serum
应用 ELISA
是否进口

Product name Certolizumab ELISA Kit
Catalog No. DF879028
Applications ELISA
Accession P01375
Stability and Storage When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Detection method Colorimetric
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 329.66 ng/mL
Background Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. It is on the World Health Organization's List of Essential Medicines. Medical uses Crohn's Disease On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy. Rheumatoid arthritis On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA in October 2009. Psoriatic arthritis On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis. Method of action Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. Clinical trials Crohn's disease Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease. Axial spondyloarthritis In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis. Rheumatoid arthritis Certolizumab appears beneficial in those with rheumatoid arthritis. References External links certolizumab+pegol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Target Certolizumab
Range 468.75 - 30,000 ng/mL
Recovery 80-120%
Alternative Names CDP870, PHA-738144, Certolizumab pegol, CAS: 428863-50-7
Clone ID \
Shipping 2-8 ℃
Note For Research Use Only.

Abinscience, founded in 2023 and located in the innovation technology center in Strasbourg, France, is the core research reagent brand of ProteoGenix. Focusing on the development and production of life science research reagents, Abinscience takes "Empowering Bioscience Discovery" as its vision, and is committed to providing high-quality and innovative biological reagent products and technical solutions for global researchers.

返回顶部